Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization

Gao, Wentao; Soloff, Adam C.; Lu, Xiuhua; Montecalvo, Angela; Nguyen, Doan C.; Matsuoka, Yumi; Robbins, Paul D.; Swayne, David E.; Donis, Ruben O.; Katz, Jacqueline M.; Barratt‐Boyes, Simon M.; Gambotto, Andrea

doi:10.1128/jvi.80.4.1959-1964.2006

Cited by 247 publications

(156 citation statements)

References 40 publications

Supporting

Mentioning

151

Contrasting

Order By: Relevance

“…rAd5 has been demonstrated to afford protection against influenza after i.m. immunization (14). Eighteen days after immunization, the animals were challenged i.n.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Genetic immunization in the lung induces potent local and systemic immune responses

Song

Bolton

Wei

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The authors note the following: "Due to an error in the evaluation of the raw ITC-data, we reported the wrong sign for the enthalpy values and correspondingly incorrect entropy values. The correct values are as follows: at pH 5.7: ΔH −54 ± 4 kJ/ mol, ΔS −68 ± 14 J/mol K and at pH 7.2: ΔH −62 ± 6 kJ/mol and ΔS −98 ± 18 J/mol K (Table 3)." The authors note that on page 5381, left column, first paragraph, line 9 "Two E1 entities dimerize upon their interaction with heparin, requiring 8-12 sugar rings to form the heparin-bridged APP-E1 dimer in an endothermic and pH-dependent process that is characterized by a low micromolar dissociation constant" should have read "Two E1 entities dimerize upon their interaction with heparin, requiring 8-12 sugar rings to form the heparin-bridged APP-E1 dimer in an exothermic and pH-dependent process that is characterized by a low micromolar dissociation constant." On page 5384, right column, third paragraph, line 23 "This reaction is driven by high entropy contributions of around 300 J/mol · K, probably resulting from the release of associated ions and water molecules upon heparin binding, as also observed for other heparin-binding proteins (reviewed, e.g., in ref. 39)" should have read "This reaction is driven by significant enthalpic contributions, probably arising from protein-protein interactions, also observed for other heparin-binding proteins (reviewed, e.g., in ref. 39)." This error does not affect the conclusions of the article.

show abstract

“…rAd5 has been demonstrated to afford protection against influenza after i.m. immunization (14). Eighteen days after immunization, the animals were challenged i.n.…”

Section: Resultsmentioning

confidence: 99%

“…The rAd35 vector expresses the mTB85 A/B + 10.4 fusion protein and also is replication incompetent. Expression of adenoviral genes is minimized by deletion of the early proteins (7,13,14).…”

Section: Methodsmentioning

confidence: 99%

Genetic immunization in the lung induces potent local and systemic immune responses

Song

Bolton

Wei

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Some of the promising approaches include recombinant protein vaccines (14), adenovirusbased technologies (15,16), and DNA plasmids (17). These strategies, especially plasmid DNA vaccines, allow for easier manipulation and faster production when compared with traditional influenza vaccines.…”

mentioning

confidence: 99%

A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

Chen

Cheng²,

Huang³

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

138

123

View full text Add to dashboard Cite

H5N1 influenza viruses have spread extensively among wild birds and domestic poultry. Cross-species transmission of these viruses to humans has been documented in over 380 cases, with a mortality rate of Ϸ60%. There is great concern that a H5N1 virus would acquire the ability to spread efficiently between humans, thereby becoming a pandemic threat. An H5N1 influenza vaccine must, therefore, be an integral part of any pandemic preparedness plan. However, traditional methods of making influenza vaccines have yet to produce a candidate that could induce potently neutralizing antibodies against divergent strains of H5N1 influenza viruses. To address this need, we generated a consensus H5N1 hemagglutinin (HA) sequence based on data available in early 2006. This sequence was then optimized for protein expression before being inserted into a DNA plasmid (pCHA5). Immunizing mice with pCHA5, delivered intramuscularly via electroporation, elicited antibodies that neutralized a panel of virions that have been pseudotyped with the HA from various H5N1 viruses (clades 1, 2.1, 2.2, 2.3.2, and 2.3.4). Moreover, immunization with pCHA5 in mice conferred complete (clades 1 and 2.2) or significant (clade 2.1) protection from H5N1 virus challenges. We conclude that this vaccine, based on a consensus HA, could induce broad protection against divergent H5N1 influenza viruses and thus warrants further study.

show abstract

“…The use of an H5N1 vaccine in poultry can be an alternative solution. A recombinant adenovirus-based vaccine that protected chickens from a lethal intranasal challenge with VN/ 1203/04 H5N1 virus was recently proposed [62].…”

Section: Prevention and Controlmentioning

confidence: 99%

“…Other investigational approaches have been explored in H5N1 vaccine development, including immunization based in the utilization of adenovirus vector [62], DNA vaccine encoding a conserved nucleoprotein antigen [70], recombinant HA produced in insect cells [71], virosomes incorporating surface glycoproteins [72], and M2 protein conjugated with the hepatitis B virus core [73]. Antiviral drugs, especially neuraminidase inhibitors, could significantly help in the control of a future influenza pandemic caused by H5N1 or other strains by reducing viral loads in patients, reducing lower respiratory tract complications and hospitalizations, as well as decreasing potential person-toperson transmission.…”

Section: Prevention and Controlmentioning

confidence: 99%

H5N1 avian influenza virus: an overview

2007

View full text Add to dashboard Cite

Avian influenza virus (H5N1) emerged in Hong Kong in 1997, causing severe human disease. In recent years, several outbreaks have been reported in different parts of Asia, Europe and Africa, raising concerns of dissemination of a new and highly lethal influenza pandemic. Although H5N1 has not been capable of sustaining human-tohuman transmission, the ability of the virus to undergo variation due to mutations and reassortment, clearly poses the possibility of viral adaptation to the human species. For this reason the World Health Organization has established that we are now in a phase of pandemic alert. Preparing for an influenza pandemic involves a great deal of awareness necessary to stop initial outbreaks, through the use of case recognition, sensitive and rapid diagnostic methods, appropriate therapeutic and preventive measures to reduce spread. Influenza pandemic preparedness involves coordinated pharmacologic and vaccinal strategies, as well as containment measures such as travel restrictions and quarantine approaches.

show abstract

Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization

Cited by 247 publications

References 40 publications

Genetic immunization in the lung induces potent local and systemic immune responses

Genetic immunization in the lung induces potent local and systemic immune responses

A consensus–hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

H5N1 avian influenza virus: an overview

Contact Info

Product

Resources

About